JP2008540528A5 - - Google Patents

Download PDF

Info

Publication number
JP2008540528A5
JP2008540528A5 JP2008511191A JP2008511191A JP2008540528A5 JP 2008540528 A5 JP2008540528 A5 JP 2008540528A5 JP 2008511191 A JP2008511191 A JP 2008511191A JP 2008511191 A JP2008511191 A JP 2008511191A JP 2008540528 A5 JP2008540528 A5 JP 2008540528A5
Authority
JP
Japan
Prior art keywords
macular degeneration
salt
subject
composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008511191A
Other languages
English (en)
Japanese (ja)
Other versions
JP5335419B2 (ja
JP2008540528A (ja
Filing date
Publication date
Priority claimed from US11/416,773 external-priority patent/US8088773B2/en
Application filed filed Critical
Publication of JP2008540528A publication Critical patent/JP2008540528A/ja
Publication of JP2008540528A5 publication Critical patent/JP2008540528A5/ja
Application granted granted Critical
Publication of JP5335419B2 publication Critical patent/JP5335419B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008511191A 2005-05-12 2006-05-04 治療用組成物および方法 Expired - Fee Related JP5335419B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68099805P 2005-05-12 2005-05-12
US60/680,998 2005-05-12
US77642606P 2006-02-24 2006-02-24
US60/776,426 2006-02-24
US11/416,773 2006-05-03
US11/416,773 US8088773B2 (en) 2005-05-12 2006-05-03 Therapeutic compositions and methods
PCT/US2006/017329 WO2006124324A1 (en) 2005-05-12 2006-05-04 Therapeutic compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012159151A Division JP5643263B2 (ja) 2005-05-12 2012-07-18 治療用組成物および方法

Publications (3)

Publication Number Publication Date
JP2008540528A JP2008540528A (ja) 2008-11-20
JP2008540528A5 true JP2008540528A5 (https=) 2012-09-06
JP5335419B2 JP5335419B2 (ja) 2013-11-06

Family

ID=37431545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008511191A Expired - Fee Related JP5335419B2 (ja) 2005-05-12 2006-05-04 治療用組成物および方法
JP2012159151A Expired - Fee Related JP5643263B2 (ja) 2005-05-12 2012-07-18 治療用組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012159151A Expired - Fee Related JP5643263B2 (ja) 2005-05-12 2012-07-18 治療用組成物および方法

Country Status (9)

Country Link
US (5) US8088773B2 (https=)
EP (3) EP1885371A4 (https=)
JP (2) JP5335419B2 (https=)
AU (1) AU2006247892B2 (https=)
CA (1) CA2608163C (https=)
DE (1) DE202006020318U1 (https=)
ES (1) ES2598277T3 (https=)
PL (1) PL2508182T3 (https=)
WO (1) WO2006124324A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
US7736860B2 (en) * 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
ES2964555T3 (es) 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
WO2013188217A1 (en) 2012-06-11 2013-12-19 Macuclear, Inc. Therapeutic formulation and methods of treatment
EP2895168A4 (en) * 2012-09-13 2016-08-31 Cba Pharma Inc TETRANDRINE MEDICINAL FORMULATIONS AND METHOD
WO2015012210A1 (ja) 2013-07-23 2015-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ縮合環化合物
US9370503B1 (en) * 2015-02-26 2016-06-21 Chi Chou Liao Compounds for treating ocular diseases
BR112020011625A2 (pt) 2017-12-11 2020-11-17 Artelo Biosciences, Inc. formas sólidas de canabidiol e usos das mesmas
US10632211B2 (en) * 2018-06-11 2020-04-28 The Regents Of The University Of California Demethylation to treat eye disease
CN110585196B (zh) * 2018-06-13 2022-11-04 郭涛 一种治疗及预防眼科疾病的药物及其应用
CN112007031A (zh) * 2019-05-30 2020-12-01 杏国新药股份有限公司 眼用制剂
EP3949958A1 (en) * 2020-08-04 2022-02-09 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound for the treatment and prophylaxis of a lipofuscin-associated disease
CN114276251B (zh) * 2021-12-07 2022-12-16 武汉大学 一种合成硝基(杂)芳烃的方法
US20240285572A1 (en) * 2023-02-27 2024-08-29 Opticgon Llc Compositions comprising nitric oxide-releasing compounds for treating choroidal vascular diseases and methods of their use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055645A (en) * 1976-02-13 1977-10-25 Merck & Co., Inc. Novel anti-hypertensive compositions
FI873429A7 (fi) * 1986-08-18 1988-02-19 Houston Biotechnology Incorporated Silmälääketieteelliset koostumukset hermodegeneraatioiden hoitoon.
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
IT1201151B (it) 1987-01-14 1989-01-27 Indena Spa Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5194434A (en) * 1991-12-03 1993-03-16 Texas A&M University System Use of OB-101 to treat ocular inflammation
US5252607A (en) 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5422166A (en) * 1993-02-12 1995-06-06 Wangner Systems Corporation Abrasion resisting edge for a forming fabric
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
CA2252962A1 (en) 1996-04-26 1997-11-06 Fujisawa Pharmaceutical Co., Ltd. Peripheral circulation improvers for ophthalmic tissues containing dihydropyridines
WO1998010758A1 (en) * 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
JP4828670B2 (ja) 1996-10-28 2011-11-30 千寿製薬株式会社 眼循環障害改善剤
WO1999044603A1 (en) 1998-03-06 1999-09-10 Sponsel William E Composition and method for treating macular disorders
US6028099A (en) 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
WO2000000194A1 (en) * 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
EP1161686A2 (en) * 1999-03-05 2001-12-12 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
AU779991B2 (en) * 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP4372905B2 (ja) * 1999-09-02 2009-11-25 興和株式会社 網膜神経細胞保護剤
US20030007971A1 (en) * 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
EP1712239A3 (en) * 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US6692759B1 (en) * 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20030171375A1 (en) * 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
AU2003287250B9 (en) * 2002-10-30 2010-01-28 Ptc Therapeutics, Inc. Identifying therapeutic compounds based on their physical-chemical properties
JP2004250347A (ja) * 2003-02-18 2004-09-09 Ajinomoto Co Inc 網膜虚血に基づく疾患の治療および／又は予防剤
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2576279A1 (en) * 2004-11-08 2006-05-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders

Similar Documents

Publication Publication Date Title
JP2008540528A5 (https=)
ES2549955T3 (es) Prevención de hipoglucemia en pacientes con diabetes mellitus de tipo 2
NZ710575A (en) Pharmaceutical compositions for the treatment of diabetes mellitus
JP2008523153A5 (https=)
JP2011528713A5 (https=)
WO2009063202A3 (en) Use of crth2 antagonist compounds
CA2608163A1 (en) Hydralazine compositions and methods
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2013500977A5 (https=)
JP2013509441A5 (https=)
JP2010540519A5 (https=)
JP2018509419A5 (https=)
JP2015013903A (ja) ２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物
JP2018518460A5 (https=)
CA2847011A1 (fr) Schema d'administration du n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide
JP2014510782A5 (https=)
JP2019524888A5 (https=)
JP2019519479A5 (https=)
Westermeyer et al. Actinomyces endogenous endophthalmitis in a cat following multiple dental extractions
WO2006120565A2 (fr) Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol, et les i0n0nes alpha- et beta-.
JP2018525447A5 (https=)
JP2008533021A5 (https=)
JP2024516003A5 (https=)
JP2021138710A5 (https=)
JP2023531930A5 (https=)